Improvements in urticaria control and quality of life among patients with chronic inducible urticaria were observed with 20 weeks of barzolvolimab.

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

With barzolvolimab re-treatment, 62% of patients with ColdU and 60% of patients with SD had a complete response at Week 20 in the OLE. These findings are consistent with the complete response rates in ...

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested. Dupilumab has been evaluated in phase 3 clinical trials in ...

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...

There are many different types of hives -- urticaria -- with many different causes. In most cases, these puffy, red, or skin-colored bumps and wheals appear suddenly due to an allergic reaction to ...

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE ...

Medically reviewed by Katlein Franca, MD Doctors use a process of elimination to diagnose chronic hives, rather than a single ...

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...